Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma
2023-508869-32-00Phase 3Authorised
- Sponsor
- Sanofi
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of isatuximab in multiple myeloma (MM) (2 arms), sponsored by Sanofi. Primary endpoints: Overall response rate and Observed concentration before dosing at steady state. Planned start Nov 2022; status: authorised.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-508869-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508869-32-00.